Abstract
Although graphene oxide (GO) has recently been considered as a highly attractive nanomaterial for future cancer imaging and therapy, it is still a major challenge to improve its invivo tumor active targeting efficiency. Here in this full article, we demonstrated the successful and significantly enhanced invivo tumor vasculature targeting efficacy of well-functionalized GO nanoconjugates by using vascular endothelial growth factor 121 (VEGF121) as the targeting ligand. As-developed GO nanoconjugate exhibits excellent invivo stability, specific invitro and invivo vascular endothelial growth factor receptor (VEGFR) targeting, significantly enhanced tumor accumulation (>8 %ID/g) as well as high tumor-to-muscle contrast, showing great potential for future tumor targeted imaging and therapy.
Original language | English |
---|---|
Pages (from-to) | 39-46 |
Number of pages | 8 |
Journal | Biomaterials |
Volume | 39 |
DOIs | |
Publication status | Published - Jan 2015 |
Externally published | Yes |
Keywords
- Graphene oxide (GO)
- Positron emission tomography (PET)
- Vasculature targeting
- VEGF
ASJC Scopus subject areas
- Bioengineering
- Ceramics and Composites
- Biophysics
- Biomaterials
- Mechanics of Materials